Informace o publikaci

Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study

Autoři

SUTTON L.A. LJUNGSTROM V. ENJUANES A. CORTESE D. SKAFTASON A. TAUSCH E. STAŇO KOZUBÍK Kateřina NADEU F. ARMAND M. MALČÍKOVÁ Jitka PANDZIC T. FORSTER J. DAVIS Z. OSCIER D. ROSSI D. GHIA P. STREFFORD J.C. POSPÍŠILOVÁ Šárka STILGENBAUER S. DAVI F. CAMPO E. STAMATOPOULOS K. ROSENQUIST R.

Rok publikování 2021
Druh Článek v odborném periodiku
Časopis / Zdroj haematologica
Fakulta / Pracoviště MU

Středoevropský technologický institut

Citace
www https://haematologica.org/article/view/9711
Doi http://dx.doi.org/10.3324/haematol.2019.234716
Klíčová slova CLINICAL IMPACTRECURRENT MUTATIONSCLONAL EVOLUTIONLABORATORY STANDARDSTP53NOTCH1SF3B1CLLBIRC3PROGRESSION
Popis Next-generation sequencing (NGS) has transitioned from research to clinical routine, yet the comparability of different technologies for mutation profiling remains an open question. We performed a European multicenter (n=6) evaluation of three amplicon-based NGS assays targeting 11 genes recurrently mutated in chronic lymphocytic leukemia. Each assay was assessed by two centers using 48 pre-characterized chronic lymphocytic leukemia samples; libraries were sequenced on the Illumina MiSeq instrument and bioinformatics analyses were centralized. Across all centers the median percentage of target reads >= 100x ranged from 94.299.8%. In order to rule out assay-specific technical variability, we first assessed variant calling at the individual assay level i.e., pairwise analysis of variants detected amongst partner centers. After filtering for variants present in the paired normal sample and removal of PCR/sequencing artefacts, the panels achieved 96.2% (Multiplicom), 97.7% (TruSeq) and 90% (HaloPlex) concordance at a variant allele frequency (VAF) 5%). We sought to investigate low-frequency mutations further by using a high-sensitivity assay containing unique molecular identifiers, which confirmed the presence of several minor subclonal mutations. Thus, while amplicon-based approaches can be adopted for somatic mutation detection with VAF 5%, after rigorous validation, the use of unique molecular identifiers may be necessary to reach a higher sensitivity and ensure consistent and accurate detection of low-frequency variants.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info